Validity of the IOTA ADNEX model for diagnosis of ovarian tumors before surgery at the National Hospital of Obstetrics and Gynecology in 2021

Abstract

Ovarian tumor is frequently occurred at any age, especially in the reproductive age. Early diagnosis of ovarian cancer is extremely important because it increases the effectiveness of treatment and reduces the mortality rate from the disease, especially in early stages of Ia. We carried out a pilot study applying
the IOTA ADNEX model in the diagnosis of ovarian tumors before surgery at the National Hospital of Obstetrics and Gynecology in 2021. The IOTA ADNEX model combines 03 clinical factors and 06 ultrasound factors to differentiate benign/malignant ovarian tumors preoperatively. This descriptive cross-sectional study on a total of 70 patients at the National Hospital of Obstetrics and Gynecology from February to August 2021 showed 62.8% of women having benign ovarian tumor and 37.2% had ovarian cancer. At the recommended cutoff of the IOTA ADNEX study (10%), using the post-operative pathology results as the gold standard, the probability of correct diagnosis
with or without CA125 result was 88.9% sensitivity; 83.87%; 75% specificity with 95% CI (0.7 - 0.88). The IOTA ADNEX model has shown good efficacy in differentiating between benign and malignant tumors and in comparing benign/borderline with the later stages of Tumor (Stage II - IV). It recommended for
a further large scale of study to be able to diagnose malignant tumors at Stage I.